- Home
- BTAI vs KPRX Comparison
BTAI vs KPRX Comparison
Compare BTAI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- KPRX
- Stock Information
- Founded
- BTAI 2017
- KPRX 1998
- Country
- BTAI United States
- KPRX United States
- Employees
- BTAI N/A
- KPRX N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BTAI Health Care
- KPRX Health Care
- Exchange
- BTAI Nasdaq
- KPRX Nasdaq
- Market Cap
- BTAI 8.3M
- KPRX 9.1M
- IPO Year
- BTAI 2018
- KPRX N/A
- Fundamental
- Price
- BTAI $1.84
- KPRX $2.90
- Analyst Decision
- BTAI Buy
- KPRX Strong Buy
- Analyst Count
- BTAI 5
- KPRX 1
- Target Price
- BTAI $34.60
- KPRX $10.00
- AVG Volume (30 Days)
- BTAI 294.8K
- KPRX 1.3M
- Earning Date
- BTAI 08-05-2025
- KPRX 08-08-2025
- Dividend Yield
- BTAI N/A
- KPRX N/A
- EPS Growth
- BTAI N/A
- KPRX N/A
- EPS
- BTAI N/A
- KPRX N/A
- Revenue
- BTAI $1,852,000.00
- KPRX $20,000.00
- Revenue This Year
- BTAI $5.03
- KPRX N/A
- Revenue Next Year
- BTAI $291.01
- KPRX N/A
- P/E Ratio
- BTAI N/A
- KPRX N/A
- Revenue Growth
- BTAI 5.47
- KPRX N/A
- 52 Week Low
- BTAI $1.17
- KPRX $2.51
- 52 Week High
- BTAI $23.04
- KPRX $4.86
- Technical
- Relative Strength Index (RSI)
- BTAI 62.90
- KPRX 43.33
- Support Level
- BTAI $1.59
- KPRX $2.87
- Resistance Level
- BTAI $2.22
- KPRX $3.22
- Average True Range (ATR)
- BTAI 0.21
- KPRX 0.18
- MACD
- BTAI 0.04
- KPRX -0.02
- Stochastic Oscillator
- BTAI 75.00
- KPRX 5.77
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.